Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
As a component of the benzamidoxime prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Additionally we are shipping MARC2 Proteins (4) and many more products for this protein.
Showing 10 out of 41 products:
Human Polyclonal MARC2 Primary Antibody for EIA, WB - ABIN453749
Havemeyer, Bittner, Wollers, Mendel, Kunze, Clement: Identification of the missing component in the mitochondrial benzamidoxime prodrug-converting system as a novel molybdenum enzyme. in The Journal of biological chemistry 2006
Show all 2 references for ABIN453749
mARC2 has a pivotal role in protecting human cells against apoptotic effects of the base analog N6-hydroxylaminopurine.
Functional characteristics of protein variants encoded by nonsynonymous single nucleotide polymorphisms in MARC1 (show MOSC1 Antibodies) and MARC2 in healthy Caucasians were determined.
human mARC-1 (show MOSC1 Antibodies) and mARC-2 are capable of catalyzing reduction of nitrite to NO through reaction with its molybdenum cofactor
Data indicate that mitochondrial amidoxime reducing components 1 and 2 together with the electron transport proteins NADH-cytochrome b5 reductase (CYB5R) and cytochrome b5 (CYB5 (show CYB5A Antibodies)) catalyze the reduction of N-hydroxylated compounds such as amidoximes.
Chlamydomonas reinhardtii ARC (show NOL3 Antibodies) has a Zn-dependent activity and protein partners similar to human MARC1 (show MOSC1 Antibodies) and MARC2.
results provide the first hints that mARC (show CCL7 Antibodies) might be involved in mitochondrial N(omega)-hydroxy-L-arginine (show GATM Antibodies) reduction and could be of physiological significance in affecting endogenous nitric oxide levels.
analysis of the nature of ligands in the Mo(V) state of the active site of mARC-2
Arc1 (show CDH1 Antibodies)(MOSC-1 (show MOSC1 Antibodies)) and Arc2(MOSC-2) proteins are monomeric in their active forms.
The presence of a novel reductive enzyme system of importance for lipid synthesis that is exclusively localized to the outer mitochondrial membrane and is composed of CYB5B (show CYB5B Antibodies), MOSC2, and a third unknown component (a CYB5B (show CYB5B Antibodies) reductase).
As a component of the benzamidoxime prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively (By similarity).
MOCO sulphurase C-terminal domain containing 2
, MOSC domain-containing protein 2, mitochondrial
, moco sulfurase C-terminal domain-containing protein 2
, molybdenum cofactor sulfurase C-terminal domain-containing protein 2
, mitochondrial amidoxime reducing component 2